International cooperation to improve access to and sustain effectiveness of antimicrobials

Christine Årdal; Kevin Outterson; Steven J. Hoffman; Abdul Ghafur; Mike Sharland; Nisha Ranganathan; Richard Smith; Anna Zorzet; Jennifer Cohn; Didier Pittet; Nils Daulaire; Chantal Morel; Zain Rizvi; Manica Balasegaram; Osman A. Dar; David L. Heymann; Alison H. Holmes; Luke S.P. Moore; Ramanan Laxminarayan; Marc Mendelson; John Arne Røttingen

doi:10.1016/S0140-6736(15)00470-5

International cooperation to improve access to and sustain effectiveness of antimicrobials

Christine Årdal, Kevin Outterson, Steven J. Hoffman, Abdul Ghafur, Mike Sharland, Nisha Ranganathan, Richard Smith, Anna Zorzet, Jennifer Cohn, Didier Pittet, Nils Daulaire, Chantal Morel, Zain Rizvi, Manica Balasegaram, Osman A. Dar, David L. Heymann, Alison H. Holmes, Luke S.P. Moore, Ramanan Laxminarayan, Marc MendelsonJohn Arne Røttingen^*

^*Corresponding author for this work

Global Public Health Consultants

Research output: Contribution to journal › Review article › peer-review

103 Citations (Scopus)

Abstract

Securing access to effective antimicrobials is one of the greatest challenges today. Until now, efforts to address this issue have been isolated and uncoordinated, with little focus on sustainable and international solutions. Global collective action is necessary to improve access to life-saving antimicrobials, conserving them, and ensuring continued innovation. Access, conservation, and innovation are beneficial when achieved independently, but much more effective and sustainable if implemented in concert within and across countries. WHO alone will not be able to drive these actions. It will require a multisector response (including the health, agriculture, and veterinary sectors), global coordination, and financing mechanisms with sufficient mandates, authority, resources, and power. Fortunately, securing access to effective antimicrobials has finally gained a place on the global political agenda, and we call on policy makers to develop, endorse, and finance new global institutional arrangements that can ensure robust implementation and bold collective action.

Original language	English
Pages (from-to)	296-307
Number of pages	12
Journal	The Lancet
Volume	387
Issue number	10015
DOIs	https://doi.org/10.1016/S0140-6736(15)00470-5
Publication status	Published - 16 Jan 2016

Bibliographical note

Funding Information:
There was no funding to write this manuscript. However, travel and accommodation to attend author meetings were paid jointly by the Center for Disease Dynamics, Economics & Policy and the Norwegian Institute of Public Health. SJH is financially supported by the Canadian Institutes of Health Research, Research Council of Norway, and the Trudeau Foundation. The opinions expressed are those of the authors and do not reflect the views of any of the authors' institutions.

Funding Information:
Several national initiatives are of a magnitude to have a global effect, even though their geographical scope is restricted. An announcement in June, 2014, stated that the £10 million Longitude Prize would focus on point-of-care diagnostics, with the creation of a “cost-effective, accurate, rapid and easy-to-use test for bacterial infections”. 26 A similar diagnostic prize proposal was announced by the US Government in September, 2014. 27 Some countries have also created partnerships with individual pharmaceutical companies; one such example is the 3·5-year collaboration between AstraZeneca and Singapore's Agency for Science, Technology and Research to develop new drugs against Gram-negative bacterial infections. 28 The Biomedical Advanced Research and Development Authority (BARDA) in the USA has partnered with GlaxoSmithKline (GSK) to develop new antibiotics with a potential of US$200 million for GSK if milestones are met. 29 Total funding from the US National Institutes of Health for antibacterial resistance averaged US$90 million per year in 2013 and 2014.

Funding Information:
There was no funding to write this manuscript. However, travel and accommodation to attend author meetings were paid jointly by the Center for Disease Dynamics, Economics & Policy and the Norwegian Institute of Public Health. SJH is fi nancially supported by the Canadian Institutes of Health Research, Research Council of Norway, and the Trudeau Foundation. The opinions expressed are those of the authors and do not refl ect the views of any of the authors'' institutions.

Publisher Copyright:
© 2016 Elsevier Ltd.

Access to Document

10.1016/S0140-6736(15)00470-5

Cite this

Årdal, C., Outterson, K., Hoffman, S. J., Ghafur, A., Sharland, M., Ranganathan, N., Smith, R., Zorzet, A., Cohn, J., Pittet, D., Daulaire, N., Morel, C., Rizvi, Z., Balasegaram, M., Dar, O. A., Heymann, D. L., Holmes, A. H., Moore, L. S. P., Laxminarayan, R., ... Røttingen, J. A. (2016). International cooperation to improve access to and sustain effectiveness of antimicrobials. The Lancet, 387(10015), 296-307. https://doi.org/10.1016/S0140-6736(15)00470-5

@article{55560194a0824abbbce03c3fda651836,

title = "International cooperation to improve access to and sustain effectiveness of antimicrobials",

abstract = "Securing access to effective antimicrobials is one of the greatest challenges today. Until now, efforts to address this issue have been isolated and uncoordinated, with little focus on sustainable and international solutions. Global collective action is necessary to improve access to life-saving antimicrobials, conserving them, and ensuring continued innovation. Access, conservation, and innovation are beneficial when achieved independently, but much more effective and sustainable if implemented in concert within and across countries. WHO alone will not be able to drive these actions. It will require a multisector response (including the health, agriculture, and veterinary sectors), global coordination, and financing mechanisms with sufficient mandates, authority, resources, and power. Fortunately, securing access to effective antimicrobials has finally gained a place on the global political agenda, and we call on policy makers to develop, endorse, and finance new global institutional arrangements that can ensure robust implementation and bold collective action.",

author = "Christine {\AA}rdal and Kevin Outterson and Hoffman, {Steven J.} and Abdul Ghafur and Mike Sharland and Nisha Ranganathan and Richard Smith and Anna Zorzet and Jennifer Cohn and Didier Pittet and Nils Daulaire and Chantal Morel and Zain Rizvi and Manica Balasegaram and Dar, {Osman A.} and Heymann, {David L.} and Holmes, {Alison H.} and Moore, {Luke S.P.} and Ramanan Laxminarayan and Marc Mendelson and R{\o}ttingen, {John Arne}",

note = "Funding Information: There was no funding to write this manuscript. However, travel and accommodation to attend author meetings were paid jointly by the Center for Disease Dynamics, Economics & Policy and the Norwegian Institute of Public Health. SJH is financially supported by the Canadian Institutes of Health Research, Research Council of Norway, and the Trudeau Foundation. The opinions expressed are those of the authors and do not reflect the views of any of the authors' institutions. Funding Information: Several national initiatives are of a magnitude to have a global effect, even though their geographical scope is restricted. An announcement in June, 2014, stated that the £10 million Longitude Prize would focus on point-of-care diagnostics, with the creation of a “cost-effective, accurate, rapid and easy-to-use test for bacterial infections”. 26 A similar diagnostic prize proposal was announced by the US Government in September, 2014. 27 Some countries have also created partnerships with individual pharmaceutical companies; one such example is the 3·5-year collaboration between AstraZeneca and Singapore's Agency for Science, Technology and Research to develop new drugs against Gram-negative bacterial infections. 28 The Biomedical Advanced Research and Development Authority (BARDA) in the USA has partnered with GlaxoSmithKline (GSK) to develop new antibiotics with a potential of US$200 million for GSK if milestones are met. 29 Total funding from the US National Institutes of Health for antibacterial resistance averaged US$90 million per year in 2013 and 2014. Funding Information: There was no funding to write this manuscript. However, travel and accommodation to attend author meetings were paid jointly by the Center for Disease Dynamics, Economics & Policy and the Norwegian Institute of Public Health. SJH is fi nancially supported by the Canadian Institutes of Health Research, Research Council of Norway, and the Trudeau Foundation. The opinions expressed are those of the authors and do not refl ect the views of any of the authors'' institutions. Publisher Copyright: {\textcopyright} 2016 Elsevier Ltd.",

year = "2016",

month = jan,

day = "16",

doi = "10.1016/S0140-6736(15)00470-5",

language = "English",

volume = "387",

pages = "296--307",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "10015",

}

Årdal, C, Outterson, K, Hoffman, SJ, Ghafur, A, Sharland, M, Ranganathan, N, Smith, R, Zorzet, A, Cohn, J, Pittet, D, Daulaire, N, Morel, C, Rizvi, Z, Balasegaram, M, Dar, OA, Heymann, DL, Holmes, AH, Moore, LSP, Laxminarayan, R, Mendelson, M & Røttingen, JA 2016, 'International cooperation to improve access to and sustain effectiveness of antimicrobials', The Lancet, vol. 387, no. 10015, pp. 296-307. https://doi.org/10.1016/S0140-6736(15)00470-5

TY - JOUR

T1 - International cooperation to improve access to and sustain effectiveness of antimicrobials

AU - Årdal, Christine

AU - Outterson, Kevin

AU - Hoffman, Steven J.

AU - Ghafur, Abdul

AU - Sharland, Mike

AU - Ranganathan, Nisha

AU - Smith, Richard

AU - Zorzet, Anna

AU - Cohn, Jennifer

AU - Pittet, Didier

AU - Daulaire, Nils

AU - Morel, Chantal

AU - Rizvi, Zain

AU - Balasegaram, Manica

AU - Dar, Osman A.

AU - Heymann, David L.

AU - Holmes, Alison H.

AU - Moore, Luke S.P.

AU - Laxminarayan, Ramanan

AU - Mendelson, Marc

AU - Røttingen, John Arne

N1 - Funding Information: There was no funding to write this manuscript. However, travel and accommodation to attend author meetings were paid jointly by the Center for Disease Dynamics, Economics & Policy and the Norwegian Institute of Public Health. SJH is financially supported by the Canadian Institutes of Health Research, Research Council of Norway, and the Trudeau Foundation. The opinions expressed are those of the authors and do not reflect the views of any of the authors' institutions. Funding Information: Several national initiatives are of a magnitude to have a global effect, even though their geographical scope is restricted. An announcement in June, 2014, stated that the £10 million Longitude Prize would focus on point-of-care diagnostics, with the creation of a “cost-effective, accurate, rapid and easy-to-use test for bacterial infections”. 26 A similar diagnostic prize proposal was announced by the US Government in September, 2014. 27 Some countries have also created partnerships with individual pharmaceutical companies; one such example is the 3·5-year collaboration between AstraZeneca and Singapore's Agency for Science, Technology and Research to develop new drugs against Gram-negative bacterial infections. 28 The Biomedical Advanced Research and Development Authority (BARDA) in the USA has partnered with GlaxoSmithKline (GSK) to develop new antibiotics with a potential of US$200 million for GSK if milestones are met. 29 Total funding from the US National Institutes of Health for antibacterial resistance averaged US$90 million per year in 2013 and 2014. Funding Information: There was no funding to write this manuscript. However, travel and accommodation to attend author meetings were paid jointly by the Center for Disease Dynamics, Economics & Policy and the Norwegian Institute of Public Health. SJH is fi nancially supported by the Canadian Institutes of Health Research, Research Council of Norway, and the Trudeau Foundation. The opinions expressed are those of the authors and do not refl ect the views of any of the authors'' institutions. Publisher Copyright: © 2016 Elsevier Ltd.

PY - 2016/1/16

Y1 - 2016/1/16

N2 - Securing access to effective antimicrobials is one of the greatest challenges today. Until now, efforts to address this issue have been isolated and uncoordinated, with little focus on sustainable and international solutions. Global collective action is necessary to improve access to life-saving antimicrobials, conserving them, and ensuring continued innovation. Access, conservation, and innovation are beneficial when achieved independently, but much more effective and sustainable if implemented in concert within and across countries. WHO alone will not be able to drive these actions. It will require a multisector response (including the health, agriculture, and veterinary sectors), global coordination, and financing mechanisms with sufficient mandates, authority, resources, and power. Fortunately, securing access to effective antimicrobials has finally gained a place on the global political agenda, and we call on policy makers to develop, endorse, and finance new global institutional arrangements that can ensure robust implementation and bold collective action.

AB - Securing access to effective antimicrobials is one of the greatest challenges today. Until now, efforts to address this issue have been isolated and uncoordinated, with little focus on sustainable and international solutions. Global collective action is necessary to improve access to life-saving antimicrobials, conserving them, and ensuring continued innovation. Access, conservation, and innovation are beneficial when achieved independently, but much more effective and sustainable if implemented in concert within and across countries. WHO alone will not be able to drive these actions. It will require a multisector response (including the health, agriculture, and veterinary sectors), global coordination, and financing mechanisms with sufficient mandates, authority, resources, and power. Fortunately, securing access to effective antimicrobials has finally gained a place on the global political agenda, and we call on policy makers to develop, endorse, and finance new global institutional arrangements that can ensure robust implementation and bold collective action.

UR - http://www.scopus.com/inward/record.url?scp=84954389558&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(15)00470-5

DO - 10.1016/S0140-6736(15)00470-5

M3 - Review article

C2 - 26603920

AN - SCOPUS:84954389558

SN - 0140-6736

VL - 387

SP - 296

EP - 307

JO - The Lancet

JF - The Lancet

IS - 10015

ER -

International cooperation to improve access to and sustain effectiveness of antimicrobials

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this